Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CABB-X
- Development stage
- Preclinical
- Lead developer
- LimmaTech Biologics
- Modality
- Vaccines & Immunotherapeutics
01
Overview
CABB-X is a preclinical vaccine candidate being developed by LimmaTech Biologics for the prevention of Streptococcus pneumoniae infections. The program is part of LimmaTech's focus on developing vaccines against antimicrobial-resistant pathogens using specialized vaccine technologies. While specific details regarding the vaccine's molecular composition or valency are not explicitly provided in the current pipeline summary, it is designed to target Streptococcus pneumoniae, a major cause of invasive bacterial diseases such as pneumonia, meningitis, and sepsis. The vaccine is currently in the preclinical stage of development.
Beyond the preview
Go deeper on CABB-X.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CABB-X.